INTRODUCTION
Although Jacobi perfused isolated organs with blood in 1895, the development of artificial blood pumps started 50 years ago (1) . In 1930 Gibbs described an artificial heart consisting of two pumps with four valves. Bypassing the original heart with that device animals were successfully perfused (2) .
Artificial blood pump development and investigations by Kolff and his group in Cleveland led to the first successful implantations in animals. In 1958 dogs were successfully perfused and in 1965 Nose reported the 31-hour survival of a calf. Twenty years later calves survived over 300 days and a survival of 353 days was achieved in 1987 by Pierce and his group (3) . In 1965 Spencer described the first clinical use of a left ventricular assist device (LVAD) (4) .
The first clinical total artificial heart (TAH) implantation as a bridging procedure to transplant was done by Cooley in April 1969 who used a device constructed by Liotta. A 47-year-old patient suffering from a heart aneurysm underwent resection and developed post-cardiotorny shock. Intra-operatively myocardial contraction remained weak and arterial mean pressures were around 40 mmHg. After implantation of the Liotta artificial heart cardiac output increased to 4.5 1/ min. Postoperatively, the patient was awake and after 3 days he received a human heart. However, renal function did not improve, and severe pneumonia led to respiratory insufficiency. The patient died 32 hours after heart transplant (HTX) (5) .
Olsen reported a series of experiments which started in 1987 with the use of twin calves kept up to 74 days on TAH in order to test bridging to cardiac transplantation. He and his group demonstrated the technical feasibility of cardiac transplantation after several months of bridging. In 1982 the first permanent human TAH implantation was done by DeVries who implanted the Jarvik device in the patient Barney Clark who survived 112 days (6) . In 1985, Copeland in Tucson (Arizona), treated a patient by a two-stage tran-splantation; he has since made a full recovery and returned to full-time work (7) .
Although single blood pump implantations were reported before, the use of artificial hearts and assist devices in clinical routine only became feasible in 1985. Between 1969 and 1984 only four TAH were used. In 1985 eight artificial hearts were implanted, six Jarvik hearts, one Penn State heart and one Phoenix heart (8) . Up to now clinical TAH and VAD-bridging has been performed by at least 20 teams in 10 countries (Austria, Czechoslovakia, Canada, France, Germany, Great Britain, Japan, Russia, Sweden, USA), and about 10 different devices have been used. The Jarvik heart is the most frequently used TAH.
Systems
Artificial blood pump systems consist of three main components: the blood pump for pulsatile or continuous blood flow, the driving unit and the power supply. It is a widely held opinion that the future goal should be to implant all TAH or VAD components. TAH devices currently used in clinical practice are mainly partial implantable systems with the driving unit outside and the ventricles implanted orthotopically into the body. The pumping ventricles are connected to the driving unit by transcutaneous drive lines. In most of the clinically used VAD systems the ventricles also remain outside the body and are connected with the blood circulation by blood tubes. Partial implantable systems involve a higher risk of infection. However the exchange or repair of damaged mechanical parts is extremely difficult in completely implanted systems.
As has been demonstrated by the VAD and TAH implantations done to date, the partially implantable system is sufficient to provide circulatory support in the course of a two-stage heart transplantation.
All TAH systems are pulsatile and mainly gas-driven membrane pumps. The available VAD systems are in the configuration either of one or two pulsatile membrane pumps or of one or two centrifugal pumps which produce a continuous blood flow. With those systems adequate treatment of circulatory deterioration became feasible.
Indications for TAH or VAD as a bridge to transplan tation
Up to now about 95% of all TAH and about 30% of all VAD were used for bridging to transplantation. The remaining 70% of VAD served for restoration of postcardiotomy heart failures. Clinical experience has shown that TAH and VAD systems function well enough to be used as a bridge to transplantation.
During the last few years there has been a sharp rise in the number of clinical heart transplantations. In 1980 for example, not more than 95 heart transplantations had been performed worldwide but this had risen to 1,400 by 1986 (ISHT-Registry). In 1987 more than 2000 transplantations were performed worldwide. This rapid increase was mainly due to the improvement of immunosuppressive therapy with cyclosporin as the major component. Using triple immunosuppressive therapy with cyclosporin, azathioprine and steroids the actuarial survival rate has risen to 84% in the last two years.
These good results encouraged heart surgeons to start transplantation programs. The rising number of heart transplantations concomitantly increased the demand for donor organs, and patients' registries had to be invented as a consequence. Preoperative waiting lists had to be established and for our transplant candidates in Vienna it takes 25 ± 18 days (shortest time 1 day/ longest time 84 days) until a donor heart can be found via Eurotransplant. Waiting for a suitable donor heart results in many cases in acute cardiac deterioration. In 1987, 381 patients received a human heart via Eurotransplant but 91 patients on the recipients list (16%) died before transplantation could be performed. Reports from USA show that 24% of patients accepted for cardiac transplantation died while awaiting their donor heart (9) . According to our records covering 78 HTX patients, about 30% die on the recipients list. This unsatisfactory situation could be partly improved by temporary circulatory assistance such as TAH bridging or VAD implantation. The following 78 groups of patients developing acute irreversible mono-or biventricular cardiac failure are also potential candidates for temporary mechanical circulatory support: 1) HTX candidates developing acute cardiac deterioration; 2) patients who cannot be weaned off the extracorporeal circulation (ECC) after open heart surgery.
As to point 2), 10% of 14200 patients at the Texas Heart Institute recovered only by measures like catecholamine substitution or IASP implantation after open heart surgery. For 1% (about 150 patients) even these measures remained insufficient (10) . For these patients, the temporary orthotopic implantation of a TAH or a VAD can be life-saving to maintain circulation and improve organ functions during bridging to transplantation.
Hemodynamically, the indication for ventricular assist, in some cases leading to bridging, is a low cardiac index with values of about 2 l/m 2/min, atrial pressures of about 20 to 25 mmHg and systolic blood pressure below 90 mmHg, provided that intra-aortic, balloon pumping (IASP) and cardiac drug treatment failed to improve the patients' situation (11) .
Contraindications for bridging with TAH or VAD are at the same time contraindications for HTX. Therefore, patients aged over 60 years, with pulmonary hypertension, systemic infection, "irreversible" organ damage, severe atherosclerosis, drug or alcohol abuse, psychogenic instability or severe diabetes should not be accepted as bridging candidates. In our group, however, we observed a decrease of pulmonary pressures and an improvement of renal and hepatic function during TAH perfusion (12) . Thus it is not always easy to decide whether to bridge or not. Cabrol and his group showed that the outcome of a two-stage transplantation was better in patients with acute cardiac deterioration than in patients with chronic deterioration. Cabrol reported that out of 25 bridged patients, those who developed sudden cardiac decompensation had 75% success on being transplanted in comparison to 44% success in patients with chronic heart failure. Additionally, patients aged 40 years or less had 80% success on being transplanted in comparison with 25% in older patients (13) .
In cases of acute cardiac deterioration with acute organ failure and "not-fixed" elevated pulmonary artery pressures bridging can bring the patient to a clinical condition that meets HTX criteria. The younger patient with acute cardiac deterioration leading to acute renal failure and elevated pulmonary pressures is also a candidate for TAH or VAD bridging. The recovery of organ functions that offers the possibility for subsequent transplantation may be achieved during artificial circulation.
VAD or TAH as a bridge to transplantation?
Clinical experience and the availability of both systems has shown that bridging is feasible with both systems. From the outset of clinical VAD or TAH implantations in 1985 it was established that biventricular failure is an indication for TAH and monoventricular failure is an indication for VAD. Similar to TAH results, it could be shown that biventricular VAD also leads to sufficient circulatory restoration. Experimental and clinical investigations showd that in many cases right heart insufficiency could be managed with cardiogenic drugs (26) . So we accept from experience that even biventricular failure may be treated with a single left ventricle assist in a large percentage of the cases. The real contraindications to VAD implantation, which consequently require TAH implantation, are as follows: 1) A VSD due to a penetrating septal myocardial infarction; 2) thrombotic material in the diseased heart, possibly causing embolism; 3) severe valve dysfunction (e.g. severe aortic valve insufficiency) . An additional advantage of VAD is that the pump tubes can be implanted without ECC.
RESULTS

Implantations
Since 1985 more than 130 TAH implantations have been performed (Dr. Joyce, Minneapolis Heart Institute; personal communication).
The TAH implantation rate rose sharply from 1985 to 1986 when 43 patients received an artificial blood pump system. In 75% the pneumatic Jarvik 7 heart was used as an orthotopically implanted mechanical device. Between 1969 and 1984 only four implantations were done and two of Cooley's patients underwent a two-stage transplantation and received a human heart. In 1987,48 patients got an artificial heart and 58% were transplanted. This implantation frequency is in drastic contrast to the 17,000 to 35,000 TAH candidates each year, estimated by the National Heart, Lung and Blood Institute (15) . This discrepancy may be explained by two aspects: 1) using the available TAH systems the results of long-term implantations were disappointing. During an implantation time between 227 (Stenberg, Sweden) and 622 days (Schroeder, USA) all patients developed thromboembolism leading to major or minor strokes. The patient Clark who was on TAH 112 days, got an infection. Thus, thromboembolism and infection were the significant limiting factors in the use of an artificial heart as long-term cardiac replacement. Results were better with two-stage transplantation. Therefore the indication for TAH implantation had to be limited to transplant candidates and transplantation itself is limited by the availability of donor organs; 2) using the systems available today the care of aTAH patient is still too intensive to keep more than 10,000 TAH recipients each year on artificial circulation.
Discharge and survival rate
Out of 200 reported patients who received a mechanical device for bridging, 51% of TAH recipients and 48% of the left-, right-, or biventricular VAD recipients could be discharged after transplantation (Fig. 1 ) Dr. Joyce, Minneapolis Heart Institute and Dr. Pae, Hershey Medical Center, Pennsylvania: personal communication). In 65% of the VAD recipients the biventricular support was used, 33% received a left VAD and 2% a single right VAD (Fig. 2) . Using the single ventricular support 50% could be discharged from hospital. After biventricular support 47% were discharged. Subsequently 63% of the TAH patients and 74% of the VAD patients were transplanted. Although the percentage of two-stage transplants is higher for VAD than for TAH patients, the rate of patients discharged is approximately the same.
If we include all data between 1969 to 1987 and exclude the recent results of 1988, patients on artificial heart for bridging have a long-term survival rate of about 30% as compared to 46% after transplantation ( Fig. 3 ).
Which VAD system is superior, pulsatile or centrifugal?
Although pulsatile VAD bridging was used in 73% of the cases reported, clinical experience showed that centrifugal VAD also leads to a discharge rate of 44%. Considering the results with pulsatile VAD, it appears that with both systems adequate short-term bridging is possible, leading to two-stage transplantation with about 40 to 50% success.
Should we recommend bridging to transplantation?
Two-stage transplanted patients have a short survival rate of about 40 to 50% and resemble high-risk transplant candidates as compared to the one-stage transplanted patients whose survival rate is about 80%. Considering the limited availability of donor hearts, two-stage transplantation means a waste of donor organs as was pointed out by Annas in the Hastings Center report in 1985 (16) . Considering the indications for clinical TAH or VAD application and the 80 50% of the patients, who got a LVAD or RVAD and 47% of the patients, who got a BVAD could be discharged. outcome of the reported cases, use of mechanical circulatory support should be restricted to young patients « 40 ye-ars) with acute cardiac deterioration.
Clinical experience with patients who had acutely rejected a previously transplanted heart and were subsequently bridged is particularly disappointing. From June 1985 to January 1987 nine patients received a TAH after acute rejection. Only four could be transplanted a second time but only one patient survived. The duration of TAH bridging was between 1 and 396 days. The patient who survived was bridged over 12 days. The poor outcome may be explained first by the susceptibility to infection of immunosuppressed patients, and second, by the active immunorejection profiles against most available donor hearts. Two long-term TAH recipients who stayed on artificial circulation for 243 and 396 days developed transplantation-preventing antibodies (8) . Therefore we should consider whether mechanical circulatory support is indicated for patients rejecting the previously transplanted heart.
Wien TAH results
Considering the improved prognosis for HTX and the incidence of acute, irreversible biventricular insufficiency in patients still on the waiting list, the demand for TAH implantation in our department became urgent. Since March 1986 five patients suffering from end-stage cardiac disease, four from cardiomyopathy and one from coronary heart disease, have received artificial hearts. We implanted the "Ellipsoid Heart" three times and the "Berlin Heart" twice. In all five patients it was possible to re-establish and maintain circulatory function and improve the patients' organ functions. Three patients fulfilled the criteria for HTX which was performed between 9 and 13 days after bridging. Two patients could not be transplanted because of infection. One of the two-stage transplanted patients died because of postoperative pulmonary artery bleeding, one because of infection and one because of acute therapy-resistant rejection 40 days after transplantation.
Complications
Complications following TAH or VAD application have mainly been bleeding problems, infection, thrombus formation and thromboembolism, device dysfunction (like valve breakdown or kinking of the drive lines), fitting problems of implanted TAH ventricles and immunoreactions interfering with subsequent HTX.
Thrombus formation and thromboembolism
Although thrombus formation could be seen in many explanted devices (17) , clinical signs of thromboembolism were rarely seen after short-duration bridging. In a review of 56 patients who were bridged to transplantation, 16% developed signs of cerebral embolism (18) . Considering the fact that all long-term TAH recipients (227 -622 days on TAH) developed strokes, the risk of thromboembolism increases synchronously with the bridging duration. In our experience of five TAH implantations, thrombus formation was seen on the left atrial inflow in one patient who underwent a two-stage transplantation after 13 days on the Berlin TAH. This patient received only heparin (200 to 1000 IU/h) for antlcoaqulatlon.
Besides blood contact with artificial surfaces, slow blood flow is an additional factor for thrombus formation. The newer, smaller designs (14) , driven with pumping frequencies above 110 beats per minute, offer better "wash-out" and thus less susceptibility for thombotic growth. The rate of thrombus formation and thromboembolism may thus be reduced and most of the fitting problems as well as device dysfunctions seem to be diminished.
Thrombotic events and infection seem to be related. Thrombus formation and embolization were often seen in TAH calves when septicemia was present (19) .
Thromboembolism is rarely described during VAD bridging, probably because of the short bridging duration. In a multicenter study of 29 VAD bridged patients with the mean bridging duration of 6.9 days, only two patients developed neurological symptoms which might have been caused by cerebral embolism. The first patient was assisted for 31 and the second for 24 days. Thrombus formation was found in both explanted devices (20) .
Considering the different devices, no uniform antithrombotic protocol exists. Drugs like heparin, dipyridamole or warfarin have been used. Although thromboembolism was also prevented using only lowmolecular dextran (21) , today anticoagulation with heparin seems necessary in the clinical use of most available devices during short-term bridging. Unfortunately prosthesis-dependent thrombus formation could not be completely suppressed with any of the clinically used antithrombotic regimens. Platelet activation and aggregation induced by artificial surfaces or shear stress may also cause local thrombus formation. Blood pump-related destruction of platelets lead to increased platelet turnover. In our experience it takes at least one week for platelet counts to rise detectably in response to successful bone marrow acti-Platelet Counts in 3 Vienna TAH Recipients anastomoses between organic tissue and artificial materials; secondly, the reduced blood hemostasis induced by anticoagulation for embolism prevention and thirdly, the reduced number and activity of the platelets during artificial or assisted circulation (23) . Therefore, careful surgical hemostasis is one of the main conditions for successful bridging. In contrast to USA reports (22) we use the fibrin glue Tissucol® to seal the stitch channels on the anastomotic sites. vation. In three of our clinically non-infected TAH recipients the platelet number rose on the 6th postoperative day (Fig. 4) .
Considering the bleeding hazard, especially in the thrombopenic state of the first week, simultaneous use of drugs inhibiting platelet aggregation, and of heparin may be risky in the early postoperative course. Antiaggregants should be administered according to individual need, taking the platelet number and the degree of platelet activation into account.
However, the ultimate assessment of the optimal antithrombotic regimen related to the patients predisposition and to the device used is a major challenge for future investigations.
Other significant complications related to shortterm use of artificial blood pumps are mainly bleeding problems and infection. Infection or preoperatively irreversible organ failure may lead to multiple organ failure, preventing transplantation.
Bleeding
Bleeding is a significant problem in the early postoperative period. Because of hemorrhage, 37% of 27 reported TAH implants required re-operation (22) . In 1988 Farrar et al. reported that out of 29 patients who received VAD as a bridge to transplantation, 21 could undergo two-stage transplantation. About 40% of these VAD patients had severe bleeding problems (21) .
Bleeding hazard in patients on artificial circulation is increased by the following factors: firstly, the surgical
Infection
Owing to transcutaneous driving lines, catheters and intracorporeal artificial surfaces, the risk of infection during TAH pumping is high. At the 29th meeting of the Austrian Surgical Association, G. Peters (24) pointed out the problems of infections in patients with intracorporeal plastics. In particolar mucus-encapsulated bacteria grow on plastic surfaces prevented by their capsule. Most of the patients on TAH who could not be transplanted suffered from incurable infections (23) .
Two of our patients on TAH died from sepsis and did not reach transplantation. In one patient infection started after HTX. Since we lost two patients because of sepsis while still on TAH we consider that infection during bridging is a nearly incurable and lethal complication. The septic course of our TAH patient who was infected before artificial heart transplantation underlines that infection is a clear contraindication for TAH implantation. In this case, even though the infection was a contraindication, we made the decision for TAH implantation, since the patient was only 36 years old.
A relation between thrombus formation or thromboembolism and systemic infection should be kept in mind. On the one hand, infections are known to exacerbate thrombus formation, and on the other, permanent activation of blood coagulation or platelet aggregates may contribute to reticulo-endothelial system (RES) blockade leading to infection susceptibility. Additionally device-related blood trauma may also 1ead to RES stress. Therefore the major TAH or VADrelated complications are linked pathophysiologically.
Prevention of infection and carefully performed surgical hemostasis are the most important measures for successful TAH or VAD use.
Immunological alterations related to the use ofTAH
The fatal course of a two-stage transplanted patient who developed acute rejection after 40 days raised the question of whether the artificial heart stimulated the immunological system. In our experience with 78 one-stage heart transplantations we never observed an acute incurable rejection. Stimulation of the immune system during artificial circulation or circulatory assist may be caused by different mechanisms like damage of blood cells, contact between blood and the artificial surface, administration of blood and blood products and courses of clinical or subclinical infections.
Two patients who had rejected their transplant and then received an artificial heart for more than 240 days developed very active immunorejection profiles (8) . Therefore it might be concluded that long-term TAH application results in additional stimulation of the immune system. However, three patients suffering from a viral cardiomyopathy were maintained on artificial circulation up to four days and developed rejection after transplantation. Judging from these data, bridging duration has no influence on transplant rejection. It was estimated that the viremia in these cases was responsible for the disappointing outcome.
Stelzer et al. (25) from the University of Louisville reported increased complement concentrations and a diminution of the T-helper/T suppressor ratio in TAH recipients. In two of our two-stage transplanted patients we observed low C3 concentrations before TAH
